Durable Response of Androgen Receptor-Positive Male Breast Cancer to Goserelin

Area of Science:

• Oncology
• Endocrinology
• Cancer Biology

Background:

• Triple-negative breast cancer (TNBC) is aggressive, with limited treatment options.
• The luteinizing hormone-releasing hormone (LHRH)/androgen receptor (AR) pathway is a potential therapeutic target in a subset of TNBC.
• Efficacy of LHRH/AR-targeted therapy in male TNBC is largely unexplored.

Observation:

• A male patient with androgen receptor-positive (AR+) TNBC was treated.
• The patient received multiple lines of chemotherapy prior to LHRH agonist therapy.
• A durable clinical response was observed following LHRH agonist treatment.

Findings:

• LHRH agonist therapy can be effective in male patients with AR-positive TNBC.
• This case demonstrates a successful application of LHRH/AR pathway inhibition in a rare TNBC presentation.
• The treatment resulted in a sustained positive outcome for the patient.

Implications:

• This case suggests LHRH/AR-targeted therapy is a viable strategy for select male TNBC patients.
• Further research is warranted to explore the role of LHRH/AR pathway in male TNBC.
• This finding may expand treatment options for this challenging cancer subtype.